For the last installment of the America in Focus project this year, we spoke with 14 Americans from all walks of life who are ...

Brace yourselves, Ozempic and Zepound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for ...

Despite the widespread popularity of new weight-loss medications, research suggests a non-drug alternative is significantly ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.